Scope
The AAD acne highlights list supported topical and systemic options and emphasise combining mechanisms while limiting systemic antibiotic exposure. They also identify a limited procedural recommendation and a treatment combination to avoid. This is a focused public-summary account, not a complete acne severity, pregnancy-safety or prescribing pathway.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Combine topical mechanisms appropriately
- The AAD highlights support benzoyl peroxide, topical retinoids and topical antibiotics as treatment options. This list does not establish that any one option is appropriate for every acne presentation. [1]
- Other supported topical options include clascoterone, salicylic acid and azelaic acid. The public highlights do not assign a patient-specific sequence among these treatments. [1]
- Use topical therapies that combine different mechanisms of action, as part of the guideline’s good clinical practices. [1]
Use systemic options with antibiotic stewardship
- The supported systemic antibiotic options listed are doxycycline, minocycline and sarecycline. Limit systemic antibiotic use rather than treating the list as support for prolonged unrestricted courses. [1]
- When using a systemic antibiotic, combine it with benzoyl peroxide and other topical therapies. [1]
- Combined oral contraceptives, spironolactone and isotretinoin are also supported systemic treatment options. These highlights do not specify their indications, contraindications, pregnancy precautions or monitoring requirements. [1]
Use the limited procedural recommendations as stated
Limitations and use
- This summary covers the AAD guideline highlights. Detailed recommendation strength, severity-based selection, age eligibility, duration, dosing, contraindications, pregnancy precautions and monitoring are not specified here.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acne vulgaris — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.